S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
OTCMKTS:XSNX

NovAccess Global (XSNX) Stock Price, News & Analysis

$0.0077
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$0.0076
$0.0078
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.22
Volume
256,500 shs
Average Volume
467,342 shs
Market Capitalization
$269,500.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
XSNX stock logo

About NovAccess Global Stock (OTCMKTS:XSNX)

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

XSNX Stock Price History

XSNX Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
NovAccess Global Announces $10.7 Million Financing
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Novaccess Global Inc XSNX
XSNX - NovAccess Global Inc.
NovAccess Global to Present at World Orphan Drug Congress
See More Headlines
Receive XSNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/19/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:XSNX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-4,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
34,493,000
Market Cap
$280,000.00
Optionable
Not Optionable
Beta
1.51
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Dwain K. Morris-Irvin M.P.H. (Age 56)
    MPH, Ph.D., CEO & Director
    Comp: $155.43k
  • Mr. Neil J. Laird (Age 71)
    Chief Financial Officer
  • Dr. Christopher Wheeler Ph.D.
    President of Stemvax Therapeutics

XSNX Stock Analysis - Frequently Asked Questions

How have XSNX shares performed in 2024?

NovAccess Global's stock was trading at $0.0201 on January 1st, 2024. Since then, XSNX stock has decreased by 61.7% and is now trading at $0.0077.
View the best growth stocks for 2024 here
.

Are investors shorting NovAccess Global?

NovAccess Global saw a increase in short interest in March. As of March 31st, there was short interest totaling 65,900 shares, an increase of 16,375.0% from the March 15th total of 400 shares. Based on an average daily trading volume, of 621,800 shares, the days-to-cover ratio is presently 0.1 days.
View NovAccess Global's Short Interest
.

How were NovAccess Global's earnings last quarter?

NovAccess Global Inc. (OTCMKTS:XSNX) announced its earnings results on Tuesday, February, 27th. The company reported $0.01 earnings per share (EPS) for the quarter.

What other stocks do shareholders of NovAccess Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN), Ascent Solar Technologies (ASTI) and BioRestorative Therapies (BRTX).

How do I buy shares of NovAccess Global?

Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:XSNX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners